Abstract
J Alzheimers Dis. 2026 Sep 17:13872877261488873. doi: 10.1177/13872877261488873. Online ahead of print.
ABSTRACT
In this issue Ishihara and colleagues report the development and characterization of new mouse models for Down syndrome Alzheimer's disease, the most commonly occurring genetic cause of dementia worldwide. These new models add to the growing portfolio of in vivo models of Down syndrome. In particular, the new Ts1Kei-APPswe/PS1dE9 model may be highly useful for the study and identification of novel treatment targets for late onset myoclonic epilepsy of Down syndrome. This seizure disorder is a common comorbidity of Down syndrome Alzheimer's disease affecting around half of all people with the condition and is associated with particularly adverse clinical outcomes.
PMID:42754556 | DOI:10.1177/13872877261488873